Kala Retained Earnings vs Cash Analysis

KALA Stock

USD 8.38 0.62 7.99%

Kala Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kala Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kala Pharmaceuticals is a good investment. Please check the relationship between Kala Pharmaceuticals Retained Earnings and its Cash accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

Retained Earnings vs Cash

Retained Earnings vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kala Pharmaceuticals Retained Earnings account and Cash. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Kala Pharmaceuticals' Retained Earnings and Cash is -0.43. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Cash in the same time period over historical financial statements of Kala Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kala Pharmaceuticals' Retained Earnings and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Kala Pharmaceuticals are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Retained Earnings i.e., Kala Pharmaceuticals' Retained Earnings and Cash go up and down completely randomly.

Correlation Coefficient

-0.43

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Cash

Cash refers to the most liquid asset of Kala Pharmaceuticals, which is listed under current asset account on Kala Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Kala Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Kala Pharmaceuticals account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Kala Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kala Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.At present, Kala Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 48.1 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (0.06).

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	860K	303K	348.5K	331.0K
Interest Income	664K	2.5M	2.8M	3.0M

Depreciation And Amortization Interest Income

Kala Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments
Total Assets		0.76	0.88	0.78	0.87	-0.46	0.77	0.89	0.75	0.89	0.57	-0.02	0.39	0.74	-0.08	0.99	-0.34	0.79	0.68	0.93	0.7	0.82	-0.29	0.84	0.79	0.97
Total Current Liabilities	0.76		0.61	0.77	0.6	-0.66	0.63	0.68	0.5	0.87	0.87	0.11	0.79	0.69	0.16	0.78	-0.25	0.76	0.4	0.8	0.95	0.45	-0.13	0.54	0.64	0.7
Total Stockholder Equity	0.88	0.61		0.6	1.0	-0.42	0.65	0.85	0.61	0.7	0.36	0.02	0.33	0.37	0.22	0.9	-0.05	0.66	0.54	0.75	0.51	0.67	-0.43	0.67	0.63	0.91
Other Liab	0.78	0.77	0.6		0.63	-0.8	0.65	0.65	0.56	0.95	0.61	0.47	0.59	0.72	-0.02	0.75	-0.65	0.57	0.54	0.92	0.74	0.65	0.05	0.68	0.66	0.71
Net Tangible Assets	0.87	0.6	1.0	0.63		-0.48	0.63	0.85	0.59	0.71	0.34	0.1	0.34	0.37	0.23	0.89	-0.1	0.63	0.51	0.75	0.5	0.65	-0.43	0.65	0.6	0.91
Retained Earnings	-0.46	-0.66	-0.42	-0.8	-0.48		-0.28	-0.43	-0.22	-0.66	-0.42	-0.74	-0.75	-0.45	-0.27	-0.5	0.5	-0.25	-0.01	-0.55	-0.56	-0.14	0.05	-0.17	-0.22	-0.47
Accounts Payable	0.77	0.63	0.65	0.65	0.63	-0.28		0.84	0.38	0.75	0.44	-0.19	0.38	0.65	-0.41	0.77	-0.39	0.56	0.77	0.76	0.59	0.68	-0.41	0.68	0.87	0.75
Cash	0.89	0.68	0.85	0.65	0.85	-0.43	0.84		0.37	0.74	0.36	-0.02	0.36	0.62	-0.14	0.92	-0.33	0.59	0.63	0.76	0.56	0.61	-0.66	0.61	0.73	0.94
Other Assets	0.75	0.5	0.61	0.56	0.59	-0.22	0.38	0.37		0.68	0.59	-0.13	0.19	0.56	0.05	0.68	-0.14	0.78	0.47	0.74	0.56	0.79	0.27	0.85	0.59	0.64
Long Term Debt	0.89	0.87	0.7	0.95	0.71	-0.66	0.75	0.74	0.68		0.75	0.22	0.56	0.78	-0.01	0.86	-0.54	0.79	0.65	0.98	0.87	0.75	-0.02	0.8	0.8	0.8
Net Receivables	0.57	0.87	0.36	0.61	0.34	-0.42	0.44	0.36	0.59	0.75		-0.09	0.61	0.62	0.21	0.55	-0.16	0.82	0.39	0.69	0.96	0.47	0.22	0.58	0.58	0.43
Common Stock Shares Outstanding	-0.02	0.11	0.02	0.47	0.1	-0.74	-0.19	-0.02	-0.13	0.22	-0.09		0.33	-0.03	0.3	0.01	-0.43	-0.22	-0.29	0.14	0.03	-0.19	0.18	-0.2	-0.18	0.02
Other Current Assets	0.39	0.79	0.33	0.59	0.34	-0.75	0.38	0.36	0.19	0.56	0.61	0.33		0.39	0.23	0.45	-0.07	0.33	-0.02	0.44	0.68	0.04	-0.06	0.11	0.29	0.37
Total Liab	0.74	0.69	0.37	0.72	0.37	-0.45	0.65	0.62	0.56	0.78	0.62	-0.03	0.39		-0.45	0.72	-0.69	0.58	0.54	0.76	0.68	0.61	-0.11	0.65	0.63	0.69
Short Long Term Debt	-0.08	0.16	0.22	-0.02	0.23	-0.27	-0.41	-0.14	0.05	-0.01	0.21	0.3	0.23	-0.45		-0.05	0.49	0.13	-0.29	-0.05	0.17	-0.19	0.17	-0.14	-0.29	-0.1
Total Current Assets	0.99	0.78	0.9	0.75	0.89	-0.5	0.77	0.92	0.68	0.86	0.55	0.01	0.45	0.72	-0.05		-0.31	0.77	0.6	0.88	0.7	0.73	-0.4	0.76	0.77	0.99
Short Term Debt	-0.34	-0.25	-0.05	-0.65	-0.1	0.5	-0.39	-0.33	-0.14	-0.54	-0.16	-0.43	-0.07	-0.69	0.49	-0.31		-0.12	-0.33	-0.49	-0.28	-0.33	-0.03	-0.32	-0.36	-0.32
Common Stock	0.79	0.76	0.66	0.57	0.63	-0.25	0.56	0.59	0.78	0.79	0.82	-0.22	0.33	0.58	0.13	0.77	-0.12		0.5	0.77	0.85	0.65	-0.01	0.74	0.82	0.69
Property Plant Equipment	0.68	0.4	0.54	0.54	0.51	-0.01	0.77	0.63	0.47	0.65	0.39	-0.29	-0.02	0.54	-0.29	0.6	-0.33	0.5		0.75	0.43	0.9	-0.1	0.87	0.69	0.58
Short Long Term Debt Total	0.93	0.8	0.75	0.92	0.75	-0.55	0.76	0.76	0.74	0.98	0.69	0.14	0.44	0.76	-0.05	0.88	-0.49	0.77	0.75		0.78	0.86	-0.01	0.89	0.8	0.84
Other Current Liab	0.7	0.95	0.51	0.74	0.5	-0.56	0.59	0.56	0.56	0.87	0.96	0.03	0.68	0.68	0.17	0.7	-0.28	0.85	0.43	0.78		0.49	0.03	0.59	0.71	0.59
Property Plant And Equipment Net	0.82	0.45	0.67	0.65	0.65	-0.14	0.68	0.61	0.79	0.75	0.47	-0.19	0.04	0.61	-0.19	0.73	-0.33	0.65	0.9	0.86	0.49		0.06	0.99	0.71	0.71
Net Debt	-0.29	-0.13	-0.43	0.05	-0.43	0.05	-0.41	-0.66	0.27	-0.02	0.22	0.18	-0.06	-0.11	0.17	-0.4	-0.03	-0.01	-0.1	-0.01	0.03	0.06		0.1	-0.19	-0.47
Non Current Assets Total	0.84	0.54	0.67	0.68	0.65	-0.17	0.68	0.61	0.85	0.8	0.58	-0.2	0.11	0.65	-0.14	0.76	-0.32	0.74	0.87	0.89	0.59	0.99	0.1		0.75	0.72
Non Currrent Assets Other	0.79	0.64	0.63	0.66	0.6	-0.22	0.87	0.73	0.59	0.8	0.58	-0.18	0.29	0.63	-0.29	0.77	-0.36	0.82	0.69	0.8	0.71	0.71	-0.19	0.75		0.73
Cash And Short Term Investments	0.97	0.7	0.91	0.71	0.91	-0.47	0.75	0.94	0.64	0.8	0.43	0.02	0.37	0.69	-0.1	0.99	-0.32	0.69	0.58	0.84	0.59	0.71	-0.47	0.72	0.73

Click cells to compare fundamentals

Kala Pharmaceuticals Account Relationship Matchups

Kala Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	221.6M	139.4M	86.8M	55.9M	64.3M	116.8M
Total Current Liabilities	22.2M	37.4M	25.7M	8.3M	9.6M	18.0M
Total Stockholder Equity	100.0M	16.8M	19.0M	7.5M	8.6M	8.2M
Net Tangible Assets	29.7M	100.0M	16.8M	19.0M	21.8M	21.4M
Retained Earnings	(399.8M)	(542.4M)	(587.2M)	(629.4M)	(566.5M)	(538.1M)
Accounts Payable	1.7M	2.8M	2.3M	919K	1.1M	1.0M
Cash	77.3M	92.1M	70.5M	50.9M	58.5M	79.6M
Other Assets	16.4M	47.1M	11.0M	462K	531.3K	504.7K
Long Term Debt	72.2M	78.9M	37.9M	34.2M	39.3M	43.8M
Net Receivables	9.9M	17.5M	6.5M	236K	271.4K	257.8K
Common Stock Shares Outstanding	1.0M	1.3M	1.5M	2.4M	2.8M	2.9M
Other Current Assets	2.8M	6.1M	9.0M	1.7M	2.0M	2.5M
Total Liab	121.6M	122.6M	67.8M	48.4M	55.7M	91.9M
Total Current Assets	171.4M	124.4M	85.9M	52.9M	60.8M	98.6M
Short Term Debt	3.1M	1.4M	5.0M	334K	300.6K	285.6K
Common Stock	59K	66K	2K	3K	3.5K	3.3K
Property Plant Equipment	32.5M	9.4M	4.0M	416K	478.4K	454.5K
Short Long Term Debt Total	100.9M	80.2M	43.0M	36.3M	41.8M	61.0M
Other Current Liab	17.4M	33.2M	14.1M	6.0M	6.9M	6.6M
Property Plant And Equipment Net	31.0M	4.0M	416K	2.8M	3.2M	3.0M
Net Debt	23.7M	(11.9M)	(27.5M)	(14.6M)	(16.8M)	(17.6M)
Non Current Assets Total	50.2M	15.1M	878K	3.1M	3.5M	3.4M
Non Currrent Assets Other	6.2M	9.6M	462K	301K	346.2K	328.8K
Cash And Short Term Investments	153.5M	92.1M	70.5M	50.9M	58.5M	96.5M
Liabilities And Stockholders Equity	221.6M	139.4M	86.8M	55.9M	64.3M	128.3M
Non Current Liabilities Total	99.4M	85.2M	42.2M	40.1M	36.1M	59.2M
Other Stockholder Equity	499.7M	559.1M	606.2M	636.9M	732.4M	373.2M
Property Plant And Equipment Gross	31.0M	6.9M	1.6M	3.9M	4.5M	4.2M
Non Current Liabilities Other	27.1M	4.8M	4.2M	4.1M	3.7M	3.5M
Inventory	4.6M	5.2M	8.6M	7.7M	8.8M	5.6M
Net Invested Capital	172.2M	95.7M	61.9M	41.7M	37.5M	35.6M
Net Working Capital	149.2M	86.9M	60.3M	44.5M	40.1M	78.0M
Capital Lease Obligations	28.7M	1.3M	13K	2.1M	1.9M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:

How To Invest In Kala

Details

Is Kala Stock a good investment?

Details

What is Kala Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(11.67)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.44)

Return On Equity

(4.31)

The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kala Retained Earnings vs Cash Analysis

Retained Earnings vs Cash

Retained Earnings vs Cash Correlation Analysis

Correlation Coefficient

Retained Earnings

Cash

Kala Pharmaceuticals fundamental ratios Correlations

Kala Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kala Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Current Assets
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Short Long Term Debt Total	+ 0.98	Long Term Debt
Cash And Short Term Investments	+ 0.97	Total Assets

Retained Earnings	- 0.8	Other Liab
Other Current Assets	- 0.75	Retained Earnings
Common Stock Shares Outstanding	- 0.74	Retained Earnings
Short Term Debt	- 0.69	Total Liab
Net Debt	- 0.66	Cash
Long Term Debt	- 0.66	Retained Earnings